10x Genomics, Inc.

10x Genomics Inc Class A's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, 10x Genomics Inc Class A has 130.28M shares outstanding.

As of June 30, 2026, 10x Genomics Inc Class A maintains a current ratio of 5.69, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, 10x Genomics Inc Class A posted a negative return on equity (ROE) of -9.40, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.47, reflecting losses generated across the asset base. The company generates approximately 446,266.28 in revenue per employee across its workforce of 1,210.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.04 indicates how many times 10x Genomics Inc Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, 10x Genomics Inc Class A recorded 205,695.50 in income tax expense. The company reported a pretax loss of -65.55M and -65.76M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, 10x Genomics Inc Class A generated 539.98M in revenue and converted that into -65.76M in net income, yielding earnings per share of -0.51. EBITDA reached -35.40M, while operating income came in at -80.34M.

As of June 30, 2026, 10x Genomics Inc Class A holds 483.19M in cash and equivalents against 68.97M in total debt, resulting in a net debt position of -439.85M. Total book value stands at 722.60M, with working capital of 486.81M providing operational flexibility.

10x Genomics Inc Class A produced 111.24M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.94M in capital expenditures, free cash flow totaled 106.29M - equivalent to 0.83 per share.

Over the twelve months ended June 30, 2026, 10x Genomics Inc Class A posted a gross margin of 70.03, reflecting its pricing power and cost economics. The operating margin of -14.88 and net profit margin of -12.18 provide insight into operational efficiency.